Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

NCT00836485 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Conjunctivitis

Interventions

DRUG: Ketotifen 4.0% Patch
DRUG: Placebo
DRUG: Olopatadine 0.2%
DRUG: Artificial tears

Sponsor

Senju USA, Inc.